Media Mentions
2008
Arnold I. Friede was mentioned in the July 21 issue of The Pink Sheet in an article regarding the increased influence the Accreditation Council for Continuing Medical Education (ACCME) will have under PhRMA's revisions to its code on interactions with health care professionals. "Most of the companies are even ahead of where the code is and have been moving very aggressively over the last many years," Mr. Friede said. "Under the PhRMA code the companies may not suggest content; under ACCME proposals, companies would be foreclosed from even suggesting topics."
Arnold I. Friede, Health, Life Sciences & Medical Devices, Life Sciences - Health
John M. Callahan was mentioned in the June 23 issue of Forbes.com regarding McDermott’s legal counsel to EyeCyte, Inc. in the company’s Series A funding through an agreement with Pfizer. Under the terms of the deal, Pfizer has invested $3 million in Series A Preferred shares of EyeCyte, a company that believes to have developed a way to isolate and use stem cells to cure macular degeneration, retinopathy and other leading causes of blindness in the world. Mr. Callahan provided legal services to EyeCyte supporting this arrangement.
John M. Callahan, Health, Life Sciences & Medical Devices, Life Sciences - Health
John M. Callahan was mentioned in the June 23 issue of PR-inside.com regarding McDermott’s legal counsel to EyeCyte, Inc. in the company’s Series A funding through an agreement with Pfizer. Under the terms of the deal, Pfizer has invested $3 million in Series A Preferred shares of EyeCyte, a company that believes to have developed a way to isolate and use stem cells to cure macular degeneration, retinopathy and other leading causes of blindness in the world. Mr. Callahan provided legal services to EyeCyte supporting this arrangement.
John M. Callahan, Health, Life Sciences & Medical Devices, Life Sciences - Health
Barbara A. Jones was quoted in a May 19 article published by Boston Business Journal regarding Acusphere Inc., a specialty pharmaceutical company, and their current cash crunch while they wait for FDA approval on Imagify, a blood imaging agent. Ms. Jones noted that many companies awaiting FDA approval often find it difficult to obtain funding, but eventually find success through a variety of strategies.
Barbara A. Jones, Corporate, Life Sciences & Medical Devices
Arnold Friede and Robert Nicholas were quoted in the April 2008 issue of Medical Marketing and Media regarding scientific 'free speech' being threatened. "Calls for an investigation into support for the American Heart Association (AHA) and American College of Cardiology stating are likely to convince other scientific groups not to speak out on issues of public concern," Mr. Friede and Mr. Nicholas said.
Arnold I. Friede, Robert B. Nicholas, Health, Life Sciences & Medical Devices, Life Sciences - Health
Mark J. Mihanovic was quoted on April 22 by the San Francisco Chronicle in an article regarding the fall in venture investment in start-ups in the first quarter of 2008. The article specifically discusses the impact in Silicon Valley despite its unique market. "The dynamics of Silicon Valley are different from elsewhere in the country because it has so many life sciences and technology companies that can merge with each other for strategic gain and wait out tough times," said Mr. Mihanovic. He continues, "If we had a more vibrant market, even an average market, I'd be doing two or three (life sciences) IPOs right now."
Mark J. Mihanovic, Corporate, Emerging Companies/Venture Financing, Life Sciences & Medical Devices
Stephen W. Bernstein and Jennifer S. Geetter were quoted in the February 1 issue of Mass High Tech in an article regarding the state of Massachusetts funding stem cell research. "States see it as a hot new thing, and that's debatable. But in Massachusetts we have all the raw expertise and can use legislation to springboard what's already here," Mr. Bernstein said. "State programs can clarify legal aspects. It's an opportunity for states to clear up any state regulations which may impede stem cell research. State privacy laws are a patchwork, and you can get tangled in ways the legislation didn't intend," Ms. Geeter said.
Stephen W. Bernstein, Jennifer S. Geetter, Health, Life Sciences & Medical Devices, Life Sciences - Health
Elizabeth I. Hack was quoted in the January 24 issue of Rx Compliance Report in an article regarding 2008 being a record year for pharma fraud recoveries along with surge in state, global and Part D enforcement. "Another important signal is that the AWP matters brought by the state are continuing to move forward at a faster pace than the Multi-District Litigation (MDL) in Boston. This is evidenced by the fact that next month Alabama will be the first state to bring to trial the state consumer fraud theories relating to AWP drug pricing," Ms. Hack said.
Elizabeth I. Hack, Health, Life Sciences & Medical Devices, Life Sciences - Health
2007
William Gaede was quoted in an October 23 article published by IP Law360 regarding a federal jury's ruling that Amgen Inc.'s patents were infringed by Roche Holding AG's generic drug Mircera. Mr. Gaede represented Amgen in the case along with others from McDermott. "We're thrilled with it…It's a terrific victory for Amgen," Mr. Gaede commented.
William Gaede, Intellectual Property, Media & Technology, Life Sciences & Medical Device Litigation, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
Stephen Bernstein was quoted in the April 30 issue of The National Law Journal on law firms' involvement in the BIO conference in Boston. Mr. Bernstein mentioned the Firm's involvement in the conference as chairs of panel discussions, "We have gone for the substance of what the conference is about," and he also mentioned the Firm's evening reception.
Stephen W. Bernstein, Health, Life Sciences & Medical Devices
Astrid R. Spain was quoted in the January 21 edition of The Star-Ledger in an article discussing the case regarding Sanofi-Aventis' patent for clopidogrel bisulfate, the chemical name for Plavix, which the drugmaker co-markets with Bristol-Myers. The companies are expected to prevail in their patent-infringement suit against Apotex. Ms. Spain commented, "There isn't anything remarkable about the merits that are being argued. The arguments are pretty ordinary. The science behind it is not that complicated and Apotex is going to have an uphill fight on the merits."
Astrid R. Spain, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
David A. Gay, Ph.D. was quoted in the January 10 issue of The Baltimore Sun regarding the Supreme Court's decision on MedImmune patent case. Dr. Gay said the decision has the potential to restructure everything.
David A. Gay Ph.D., Intellectual Property, Media & Technology, Life Sciences & Medical Devices
2006
Astrid Spain was quoted in The Deal on December 4 in an article on the pharmaceutical industry in China. "I think the only strategy to deal with China is to take into account that they are moving through industrialization into a capital market society and to keep in mind that not long ago they made a shift from socialism into a capitalist society. Those things still significantly shape their business environment," commented Ms. Spain.
Astrid R. Spain, Intellectual Property, Media & Technology, International, Life Sciences & Medical Devices
Stephen Bernstein was quoted by the Boston Business Journal on December 4 in an article regarding the growth of Boston's top five venture capital-backed pharmaceutical start-up companies. "In Massachusetts, part of the reason this sector is hot is that there is good clustering of companies, academia and capital," Mr. Bernstein said. "The markets are doing quite well and there's a lot of capital chasing a number of companies positioned in that three-to-five-year window when return is expected."
Stephen W. Bernstein, Health, Life Sciences & Medical Devices
Joan Griffin was quoted in The Boston Globe on December 4 in regard to a trademark dispute between Lunesta and Tharos Laboratories, Inc. "In the old days, you'd say a logo didn’t really matter, because these things are prescribed by doctors," commented Ms. Griffin. "But if they're advertising it on TV, they're aiming it at consumers, and the logo matters." She continued and said Tharos could face a tough road proving that a big green moth is causing confusion with its blue butterfly.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices
Astrid Spain was quoted in the October 5 edition of The Baltimore Sun in an article discussing the arguments presented before the U.S. Supreme Court in the MedImmune Inc. v. Genentech Inc. Ms. Spain commented, "Licensing relationships are such an integral part of everyday business, that I think there's a lot of interest from the corporate world in this case." She was also quoted in an interview with Bloomberg News. A ruling in MedImmune's favor would put companies seeking a license "in a totally different position in that power balance" in negotiations.
Astrid R. Spain, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
David Gay and client Glen Evans were featured in the August edition of IP Law & Business as a "dynamic duo." Mentioned in two articles, David and Glen's inventor-lawyer relationship was showcased highlighting the ingenuity of the attorney that allowed the inventor to reap maximum value from his ideas. The story discusses the biotech start-up founded by Glen Evans and David's role in ensuring that the intellectual property was in synch with the company's business goals. The company was sold to Johnson & Johnson in 2004 for millions of dollars.
David A. Gay Ph.D., Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
William Gaede was recognized in American Lawyer's (February 2006) "Star Laterals of the Year" as one of the 10 most significant lateral moves in the United States in 2005.
William Gaede, Intellectual Property, Media & Technology, Life Sciences & Medical Devices
2005
Mauricio Flores was quoted in The Wall Street Journal on June 14 in regard to the U.S. Supreme Court's decision, vacated and remanded, in Merck KGaA v. Integra LifeSciences (03-1237), in which Mauricio argued before the Court on behalf of Integra. Mauricio was also quoted in the Associated Press, Law.com, Washington Post,Los Angeles Times, The New York Times, San Diego Union-Tribune and San Francisco Daily Journal.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech, Trial
Mauricio Flores was quoted in the June issue of Corporate Legal Times in an article reporting on Merck KGaA v. Integra LifeSciences, et al. which was argued before the U.S. Supreme Court this spring. Integra argued that Scripps was conducting research for a lot of commercial reasons unrelated to a FDA application. "We think that the evidence show that what was going on at Scripps was not FDA related, that they were just trying to come up with some FDA justification after the fact," commented Mr. Flores, who argued the case before the Supreme Court on behalf of Integra. "They were doing it to generally strengthen the scientific premise of Merck's drug program. The premise is that if you inhibit a particular receptor with anything, whether its' an RGD peptide or something completely different, you can inhibit the growth of blood vessels. So that's a non-FDA related purpose."
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
Mauricio Flores was quoted in the April 21 issue of the San Diego Union-Tribune in regard to representing Integra LifeSciences before the U.S. Supreme Court.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
Cathryn Campbell was quoted in the New York Times on April 19 and the Boston Globe and Los Angeles Times on April 20 regarding our representation of Integra LifeSciences in Merck RGaA v. Integra Life Sciences before the U.S. Supreme Court.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
Mauricio Flores was quoted, "Justices to Review Patent Safe Harbor," an article that appeared in the April 11 issue of The National Law Journal regarding Merck KGaA v. Integra LifeSciences. Mr. Flores commented on the case which is scheduled to be argued before the U.S. Supreme Court on April 20. The article examined the Merck case and questioned "how far down the chain of research and experimentation into new drugs does a federal safe harbor statute reach to protect drug manufacturers from liability for patent infringement."
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
Cathryn Campbell and Mauricio Flores were quoted in the April 1 issue of San Diego's The Daily Transcript in the article, "Patent disputed leads local law firm to the U.S. Supreme Court." Mr. Flores will present the case for Integra LifeSciences, which is charging Merck KGaA with patent infringement. Mr. Flores states, "it's always exciting to argue something in front of the highest court in the land, especially something this important." Dr. Campbell notes that "this is a very important case and it's been recognized as such," and "everyone from big pharmaceutical companies and biotech firms to bar associations and law professors will be watching the proceedings."
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
2004
Judith Toffenetti was quoted in the December 10 issue of The Miami Herald regarding ways a company might stretch the life of patent or created new patents for older drugs. Ms. Toffenetti said different crystal forms, different dosage forms, molecular variations on the drugs and combinations of drugs are among the ways to extend the life of a drug.
Judith L. Toffenetti, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
Cathryn Campbell was quoted in the November 2004 issue of California Lawyer in regard to the success of the biotech industry, now exceeding $39 billion and the success is due in large part to the amount of litigation. Cathryn Campbell states, "[V]irtually every product that's come out of biotech has been the subject of a lawsuit." "Those lawsuits have included everything from infringement to inventorship to licensing to whether royalties have been sufficient." Cathryn Campbell explains how much of the litigation stems from the early licensing agreements and how the royalty base is effected. She concludes that "[E]ven though we're getting more sophisticated, there will be a lot of disputes, because of the amount of money at stake and the difficulty of writing prospective licenses...."
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
Global Counsel 3000 (Practical Law), a law-related resource site, recently recommended MWE's Miami office as a top firm for Company and Corporate Transactions, where the office is a leader in health care transactions. In addition, Paul Radensky was recommended nationally for his work in the Life Sciences/Regulatory area.
Paul W. Radensky M.D., Corporate, Life Sciences & Medical Devices
2003
McDermott Will & Emery was mentioned in the August 2003 issue of Intellectual Property Today for successfully representing Burnham Institute and Integra LifeSciences, by obtaining a significant victory related to patent infringement in the context of biomedical research.
Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP, Litigation - IP, Media & Tech
Peter Resnik was quoted in Mass High Tech on June 16 in regard to life sciences companies that have been threatened as plaintiff attorneys are winning huge settlements against these pharmaceutical and biotech companies. "The tort system seems out of control. The amount that some juries are awarding is totally out of proportion," commented Mr. Resnik.
Peter L. Resnik, Life Sciences & Medical Devices, Trial
Cathryn Campbell was quoted in the April 11 issue of the Boston Business Journal regarding how companies merge their intellectual property during a corporate merger or acquisition. "Often, firms merge to get the intellectual property, particularly in the biotech and pharmaceutical industry." Ms. Campbell continued, "Before the merger, they were in essence competitors; now they own the competing technologies. You have two companies working in the same field, or they're working to find treatments for the same disease, and they'll realize by combining technologies and approaches they're in a better position to tackle that."
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
McDermott Will & Emery was mentioned in the April issue of Intellectual Property Today regarding the acquisition of Campbell & Flores, a San Diego-based biotechnology intellectual property law firm.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices
McDermott Will & Emery was mentioned in the April 1 issue of Managing Intellectual Property regarding the addition of the 10-strong biotech IP boutique Campbell & Flores.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices
McDermott Will & Emery was mentioned in the March 4 issue of San Diego Daily Transcript in regard to adding 10 lawyers and professionals from Campbell & Flores, a San Diego-based biotechnology intellectual property law firm.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
McDermott Will & Emery was mentioned in the February 10 issue of the Global Competition Review in regard to advising Centerpulse on the sale of its heart valve entity, Carbomedics, to Snia S.p.A.
Antitrust & Competition, Life Sciences & Medical Devices, Mergers & Acquisitions
Thomas Weinberger, Scott Megregian, Todd Garvelink, Toby Kusmer, Daphne Trotter, Robert Nicholas, Felise Feingold, Jason Ment, Michael Serafini, Eric Halverson and Nathan Beaver were mentioned as the McDermott legal team advising Centerpulse's Carbomedics in its acquisition by Snia S.p.A. in the January 6 issue of the New Jersey Law Journal.
Life Sciences & Medical Devices, Mergers & Acquisitions
McDermott Will & Emery was mentioned as counsel for Centerpulse in its sale of Carbomedics to Snia S.p.A. in the January 5 issues of Medical Devices & Surgical Technology Week and Heart Disease Weekly.
Life Sciences & Medical Devices, Mergers & Acquisitions
McDermott Will & Emery was mentioned as counsel for Centerpulse in its sale of Carbomedics to Snia S.p.A. in the January 1 issue of Biotech Week.
Life Sciences & Medical Devices, Mergers & Acquisitions
2002
Peter Resnik and McDermott Will, and Emery's Life Science Litigation Practice was profiled in "Biotech's Warrior," a feature article that appeared in the Boston Globe on Wednesday, October 16, 2002. The article, which appeared on the front page of the Business Section profiled Peter's biotech litigation work, including Fen-Phen and StarLink.
Peter L. Resnik, Life Sciences & Medical Devices, Trial
McDermott Will & Emery was mentioned in the July 8 issue of Crain's Chicago Business in regard to adding professional staff to advise on specific issues. It was mentioned that McDermott has hired nurses for pharmaceutical clients and a canon lawyer/nun for Catholic hospital clients.
Catholic Organizations, Health, Life Sciences & Medical Devices
Stephen Bernstein was quoted in the May 7 issue of InfoWorld Daily News in regard to how biotechnology companies are preparing for the HIPAA deadline. According to Mr. Bernstein HIPAA has not been a top priority. "For the most part, biotechnology companies are not covered entities, but there area number of hidden traps and pitfalls, where some companies may be covered entities or hybrids," he commented.
Stephen W. Bernstein, Health, HIPAA, Life Sciences & Medical Devices
Cathryn Campbell was honored by UCSD Athena, an organization that unites women executives in high tech and life sciences companies and the firms that support them, receiving the organization's Individual Pinnacle Award in the service category in April 2002. Click here to reed the USCD Athena press release.
, Intellectual Property, Media & Technology, Life Sciences & Medical Devices, Life Sciences - IP
Toby Kusmer was quoted in the March 29 issue of the Boston Business Journal in regard to the lawsuits arising in the biotech industry. The article mentions that biotech lawsuits sometimes get emotional because the executives involved invented the technology or product in dispute.
Toby H. Kusmer PC, Intellectual Property, Media & Technology, Life Sciences & Medical Devices
2001
McDermott's U.S. partners were included in a list of biotech M&A deals in the second half of 2000 in the January 25 issue of Legal Week.
